This includes GOPC-ROS fusions for which ROS inhibitors such as crizotinib and lorlatinib are available, RET fusions with CCDC6 and PCM1 which may be amendable to cabozanitinib and vandetanib therapies, ETV-NTRK fusions for which larotrecitinib and entrectinib have been used, and MET-PTPRZ1 fusions which have been implicated in IDH-mutant high grade astrocytomas and for which MET-specific kinase inhibitors are under investigation [13, 17, 19, 27, 30, 40, 43]. This evidence concerns the gene ROS1 and astrocytoma (excluding glioblastoma).